Bayer Intellectual Property Gmbh

Bayer Healthcare Aktiengesellschaft

Bayer Pharma Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Pharmaceuticals Corporation

Jens-Kerim Ergüden

Peter Kolkhof

Ingo Flamme

Hanno Wild

Kai Thede

Felix Oehme

Joachim Schuhmacher

Mario Jeske

Friederike Stoll

Hartmut Beck

Karl-Heinz Schlemmer

Metin Akbaba

Jörg Keldenich

Alexander Kuhl

Gunter Karig

Joachim Hütter

Dieter Lang

Rolf Grosser

Lars Bärfacker

Heike Heckroth

Paul Naab

Marcus Bauser

Nils Burkhardt

Dietmar Flubacher

Heike Gielen-Haertwig

Maria Niewöhner

Santiago Figueroa Perez

Jürgen Stoltefuss

Johannes-Peter Stasch

Andreas Knorr

Adrian Tersteegen

Ulrich Rosentreter

Martin Hendrix

Walter Hübsch

Kerstin Henninger

Peter Nell

Thomas Krahn

Olaf Weber

Stefan Weigand

Nicole Diedrichs

Barbara Albrecht

Stephen Boyer

Arno Friedl

Reinhard Jork

Dirk Brohm

Sabine Arndt

Dagmar Schauss

Michael Brands

Irene Gerlach

Michael Schauer

Volker Hinz

David Brückner

Christian Schröder

Thorsten Oliver Repp

Thorsten-Oliver Repp

Andrea Sewing

Mark Miglarese

The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

Substituted dihydropyrazolones for treating cardiovascular and hematological diseases

The present application relates to novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases

The present application relates to novel phenylaminothiazole derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of hypertension and other cardiovascular disorders.

Substituted phenylaminothiazoles and use thereof

The present application relates to novel substituted dipyridyldihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

Substituted dipyridyl-dihydropyrazolones and use thereof

Substituted dihydropyrazolones and use thereof as HIF-prolyl-4-hydroxylase inhibitors

Dipyridyl-dihydropyrazolones and their use

The present application relates to novel 4-chromenonyl-1,4-dihydropyridinecarbonitriles, processes for their preparation, pharmaceutical compositions containing them, and their use for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

4-Chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof

The present application relates to novel 4-chromenonyl-1,4-dihydropyridines, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.

4-Chromenonyl-1,4-dihydropyridines and their use

The invention relates to compounds of formula (I), to a method for the production thereof, and to the use of the same as pharmaceuticals for the treatment of diseases in humans and/or animals 

Substituted 2,5-diamidoindoles as ECE inhibitors for the treatment of cardiovascular diseases

The invention relates to new imidazotriazines, processes for their preparation, and their use for the production of medicaments for the treatment and/or prophylaxis of neurodegenerative disorders, in particular Parkinson's disease.

Imidazotriazines for use as phosphodiesterase inhibitors

The present invention relates to pyrrolo[2.1-a]dihydroisoquinolines which are inhibitors of phosphodiesterase 10a and can be used for combating cancer.

Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors

Growing community of inventors

Wülfrath, Germany

Jens-Kerim Ergüden